World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
44
Citations
8018
World Ranking
4772
National Ranking
2142

Harold A. Kessler publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Harold A. Kessler sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 134 publications — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Harold A. Kessler D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Harold A. Kessler sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 44 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Harold A. Kessler is affiliated with Rush University Medical Center in the United States. The affiliation indicates a professional connection to a well-known institution involved in medical research and healthcare.

Although there is no detailed list of specific research papers, frequent co-authors, publication venues, or book publications associated with Harold A. Kessler in the available data, the association with Rush University Medical Center suggests involvement in medical or clinical research.

The absence of explicit information on main fields of study, subfields, or specific topics of work precludes detailed discussion on the scientist's research focus areas. Similarly, there is no record of awards or distinctions granted to this individual to contextualize their standing in their academic or clinical domain.

Due to limited available information, a comprehensive overview of Harold A. Kessler's academic contributions, publication history, or research impact cannot be established beyond the institutional affiliation.

Best Publications

  • Immunologic Responses Associated with 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315

    Michael Marcel Lederman;Elizabeth Connick;Alan Landay;Daniel R. Kuritzkes

  • A Controlled Trial Comparing Foscarnet with Vidarabine for Acyclovir-Resistant Mucocutaneous Herpes Simplex in the Acquired Immunodeficiency Syndrome

    Sharon Safrin;Clyde Crumpacker;Pam Chatis;Roger Davis

  • ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.

    L A Pinto;J Sullivan;J A Berzofsky;M Clerici

  • ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

    Robert L. Murphy;Scott Brun;Charles Hicks;Joseph J. Eron

  • Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.

    Hernan Valdez;Elizabeth Connick;Elizabeth Connick;Kimberly Y. Smith;Kimberly Y. Smith;Michael M. Lederman

  • HIV-Specific T-Helper Activity in Seronegative Health Care Workers Exposed to Contaminated Blood

    Mario Clerici;James M. Levin;Harold A. Kessler;Alan Harris

  • Immune Reconstitution in the First Year of Potent Antiretroviral Therapy and Its Relationship to Virologic Response

    Elizabeth Connick;Michael Marcel Lederman;Brian L. Kotzin;John Spritzler

  • A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

    Calvin J. Cohen;Susan Hunt;Michael Sension;Charles Farthing

  • Thymic Size and Lymphocyte Restoration in Patients with Human Immunodeficiency Virus Infection after 48 Weeks of Zidovudine, Lamivudine, and Ritonavir Therapy

    Kimberly Y. Smith;H. Valdez;A. Landay;J. Spritzler

  • Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy: Recommendations of an International Panel

    R J Whitley;M A Jacobson;D N Friedberg;G N Holland

  • Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

    Hernan Valdez;Kimberly Y. Smith;Alan Landay;Elizabeth Connick

  • A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS

    Jacob Lalezari;Tim Schacker;Judith Feinberg;Joseph Gathe

  • Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy.

    Richard W. Price;Constantin T. Yiannoutsos;David B. Clifford;Lawrence Zaborski

  • Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients

    Constance A. Benson;Steven G. Deeks;Scott C. Brun;Roy M. Gulick

  • Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients.

    Deborah A. Paul;Lawrence A. Falk;Harold A. Kessler;Robert M. Chase

  • In vivo analysis of Fas/FasL interactions in HIV-infected patients.

    Andrew D. Badley;David H. Dockrell;Alicia Algeciras;Steve Ziesmer

  • Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial

    Joseph J. Eron;Judith Feinberg;Harold A. Kessler;Harold W. Horowitz

  • Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

    Charles Hicks;Martin S. King;Roy M. Gulick;A. Clinton White

  • Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome.

    Harold A. Kessler;Bernard Blaauw;Joel Spear;Deborah A. Paul

  • Molecular Analysis of Decreased Interleukin-12 Production in Persons Infected with Human Immunodeficiency Virus

    Claire Chougnet;Thomas A. Wynn;Mario Clerici;Alan L. Landay

  • Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

    Mary A. Albrecht;Ronald J. Bosch;Scott M. Hammer;Song-Heng Liou

  • Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients.

    Keith Fowke;Ronald D'Amico;David Chernoff;John Pottage

  • Characterization of Viral Dynamics in Human Immunodeficiency Virus Type 1-Infected Patients Treated with Combination Antiretroviral Therapy: Relationships to Host Factors, Cellular Restoration, and Virologic End Points

    Hulin Wu;Daniel R. Kuritzkes;Daniel R. McClernon;Harold Kessler

  • Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.

    Ofelia A. Olivero;Gene M. Shearer;Claire A. Chougnet;Andrea A.S. Kovacs

Frequent Co-Authors

Alan L. Landay
Alan L. Landay The University of Texas Medical Branch at Galveston
Daniel R. Kuritzkes
Daniel R. Kuritzkes Brigham and Women's Hospital
Gene M. Shearer
Gene M. Shearer National Institutes of Health
Constance A. Benson
Constance A. Benson University of California, San Diego
Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Elizabeth Connick
Elizabeth Connick University of Arizona
Robert L. Murphy
Robert L. Murphy Northwestern University
Mario Clerici
Mario Clerici University of Milan
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Linas A. Bieliauskas
Linas A. Bieliauskas University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can expand career opportunities significantly. Many students interested in clinical applications often consider advanced nursing roles, such as nurse practitioners. Programs like the easiest online nurse practitioner programs offer flexible pathways to enter this growing field without compromising educational quality.

Specializations in mental health, such as the psychiatric mental health nurse practitioner role, are also highly relevant. Some of the best online psychiatric mental health nurse practitioner programs provide excellent clinical placement rates, ensuring hands-on experience is part of the curriculum. Affordability is another key consideration, making the cheapest pmhnp programs valuable options for many aspiring practitioners.

Understanding the financial outcomes of these career paths is crucial. The dnp salary varies by location and specialization, and examining this data can help guide educational investment decisions. Overall, combining immunology knowledge with nursing specialties offers a strong foundation for impactful, well-compensated careers in healthcare.

Best Scientists Citing Harold A. Kessler

Trending Scientists

Recently Published Articles